Breakthrough in COPD Management: GSK’s Nucala Advances Toward European Approval for Eosinophilic Patients

GSK announced a significant milestone in respiratory medicine as the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Nucala (mepolizumab) for treating uncontrolled…

Continue Reading Breakthrough in COPD Management: GSK’s Nucala Advances Toward European Approval for Eosinophilic Patients
Proof-of-Concept Trial Suggests That Tezepelumab (TEZSPIRE) Could Play a Role in Treating COPD
source: shutterstock.com

Proof-of-Concept Trial Suggests That Tezepelumab (TEZSPIRE) Could Play a Role in Treating COPD

The COURSE Phase IIa clinical trial was conducted to evaluate tezepelumab (marketed as TEZSPIRE) in people living with chronic obstructive pulmonary disease (COPD) that had a wide range of blood…

Continue Reading Proof-of-Concept Trial Suggests That Tezepelumab (TEZSPIRE) Could Play a Role in Treating COPD
STUDY: Palliative Telecare Conferred Quality-of-Life Improvements in COPD
Source: https://pixabay.com/en/upper-body-lung-copd-disease-944557/

STUDY: Palliative Telecare Conferred Quality-of-Life Improvements in COPD

Treatments and management plans exist for chronic obstructive pulmonary disease (COPD), heart failure, and interstitial lung disease (ILD). Yet despite these treatments, many people with these conditions still experience chronic…

Continue Reading STUDY: Palliative Telecare Conferred Quality-of-Life Improvements in COPD
Rare Community Profiles: AlphaID At Home Provides Accessible, Targeted Screening for Alpha-1 Antitrypsin Deficiency (AATD)
Source: https://pixabay.com/en/upper-body-lung-copd-disease-944557/

Rare Community Profiles: AlphaID At Home Provides Accessible, Targeted Screening for Alpha-1 Antitrypsin Deficiency (AATD)

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: AlphaID At Home Provides Accessible, Targeted Screening for Alpha-1 Antitrypsin Deficiency (AATD)
Dupilumab Reduces Type 2 Inflammation in People Living with COPD, Study Shares
source: shutterstock.com

Dupilumab Reduces Type 2 Inflammation in People Living with COPD, Study Shares

  The World Health Organization (WHO) reports that an estimated 3.23 million people worldwide die each year from chronic obstructive pulmonary disease (COPD), making it the third leading cause of…

Continue Reading Dupilumab Reduces Type 2 Inflammation in People Living with COPD, Study Shares

Researchers Work to Understand the Role of GDF15 in Lung Diseases Like Idiopathic Pulmonary Fibrosis

Growth differentiation factor 15 (GDF15) is expressed in normal conditions but is overly expressed when cells are under stress. It has multiple roles in different diseases and has been used…

Continue Reading Researchers Work to Understand the Role of GDF15 in Lung Diseases Like Idiopathic Pulmonary Fibrosis